Apr 22 |
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter
|
Apr 15 |
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Apr 9 |
Corcept (CORT) Completes Enrollment in Ovarian Cancer Study
|
Apr 1 |
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
|
Mar 29 |
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
|
Mar 29 |
Investing in Corcept Therapeutics (NASDAQ:CORT) five years ago would have delivered you a 114% gain
|
Mar 27 |
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
|
Mar 25 |
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
|
Mar 22 |
Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?
|
Feb 19 |
Corcept Therapeutics: Key Catalysts Ahead
|